Pulmicort sales declined 4% to $138 million. Fasenra recorded sales of $436 million in the quarter, up 13% year over year, ...

In this video, Juan Carlos Cardet, MD, of the University of South Florida (USF) Health Morsani College of Medicine in Tampa, ...

Shore Capital reiterated their buy rating on shares of AstraZeneca (LON:AZN – Free Report) in a research report report ...

Within the coming year, we will see the results of significant indication expansion opportunities for our marketed medicines, including Truqap, Enhertu, Imfinzi and Fasenra, as well as pivotal trial ...

AstraZeneca's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected ...

Fiera Capital Corp trimmed its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 5.9% during the third quarter, according to the company in its most recent filing with the Securities and ...

It is one of GSK's top drugs, with sales of $2.2 billion last year, jostling for market share with other IL-5 inhibitors, notably AstraZeneca's Fasenra (benralizumab) – dosed every four weeks ...

Total Revenue up 19% to $39,182m, driven by a 19% increase in Product Sales and continued growth in Alliance Revenue from partnered medicines Total Revenue growth from Oncology was 22%, CVRM 21%, R&I ...

U.S. President-elect Donald Trump said on Tuesday Elon Musk and former Republican presidential candidate Vivek Ramaswamy will lead the newly created Department of Government Efficiency. United ...

Melania Trump declined Jill Biden's invitation for tea at the White House as their husbands meet for the customary post-election lunch. Melania reportedly cited a scheduling conflict but sources ...

Nov. 11, 2024 — A team of scientists has used a novel approach to identify protein degraders that target Pin1, a protein involved in pancreatic cancer ... DNA Packaging Directly Affects How Fast ...

Justin Welby, the leader of 85 million Anglicans worldwide, announced his resignation days after a report found he had taken insufficient action over claims of abuse. By Stephen Castle and Mark ...